0001193125-24-084748.txt : 20240402 0001193125-24-084748.hdr.sgml : 20240402 20240402160655 ACCESSION NUMBER: 0001193125-24-084748 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240401 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240402 DATE AS OF CHANGE: 20240402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 24814225 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 8-K 1 d821049d8k.htm 8-K 8-K
Adaptive Biotechnologies Corp false 0001478320 0001478320 2024-04-01 2024-04-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report April 2, 2024 (Date of earliest event reported): April 1, 2024

 

 

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Washington   001-38957   27-0907024
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

1165 Eastlake Avenue East  
Seattle, Washington   98109
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 659-0067

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common stock, par value $0.0001 per share   ADPT   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 1, 2024, the Chief Financial Officer of Adaptive Biotechnologies Corporation (the “Company”) Tycho Peterson submitted his resignation. The resignation was voluntary and not due to any disagreement with the Company on any matter relating to its operations, policies or practices. Mr. Peterson’s planned departure date from the Company is April 5, 2024. Kyle Piskel, who has been with Company for 8 years and is currently its Principal Accounting Officer will serve as the Chief Financial Officer starting on April 8, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      ADAPTIVE BIOTECHNOLOGIES CORPORATION
Date: April 2, 2024     By:  

/chad robins/

      Chad M. Robins, Chief Executive Officer
 EX-101.SCH 2 adpt-20240401.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 adpt-20240401_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 adpt-20240401_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document and Entity Information
Apr. 01, 2024
Cover [Abstract]  
Entity Registrant Name Adaptive Biotechnologies Corp
Amendment Flag false
Entity Central Index Key 0001478320
Document Type 8-K
Document Period End Date Apr. 01, 2024
Entity Incorporation State Country Code WA
Entity File Number 001-38957
Entity Tax Identification Number 27-0907024
Entity Address, Address Line One 1165 Eastlake Avenue East
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98109
City Area Code (206)
Local Phone Number 659-0067
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.0001 per share
Trading Symbol ADPT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - d821049d8k.htm 7 adpt-20240401.xsd adpt-20240401_lab.xml adpt-20240401_pre.xml d821049d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d821049d8k.htm": { "nsprefix": "adpt", "nsuri": "http://www.adaptivebiotech.com/20240401", "dts": { "schema": { "local": [ "adpt-20240401.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "adpt-20240401_lab.xml" ] }, "presentationLink": { "local": [ "adpt-20240401_pre.xml" ] }, "inline": { "local": [ "d821049d8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-04-01_to_2024-04-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d821049d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-04-01_to_2024-04-01", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d821049d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.adaptivebiotech.com//20240401/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-24-084748-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-084748-xbrl.zip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end XML 17 d821049d8k_htm.xml IDEA: XBRL DOCUMENT 0001478320 2024-04-01 2024-04-01 Adaptive Biotechnologies Corp false 0001478320 8-K 2024-04-01 WA 001-38957 27-0907024 1165 Eastlake Avenue East Seattle WA 98109 (206) 659-0067 false false false false Common stock, par value $0.0001 per share ADPT NASDAQ false